tt_news_news - SINGLE


News, Product news
06-24, 2016
Recipharm, a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry, has formed a global partnership with Marchesini Group, SEA Vision and TraceLink to introduce new serialisation capabilities.

The announcement marks the next step in the global CDMO’s plans to invest 40 million Euros over the next three years to ensure state-of-the-art solutions for serialisation processes. The investment will ensure that pharmaceutical companies accessing Recipharm’s manufacturing services will comply with the EU Falsified Medicines Directive (EUFMD) Safety Features Delegated Regulation, which makes serialisation of licensed drug products in Europe a legal requirement from early 2019.

After assessing various vendors, Recipharm selected Marchesini Group and SEA Vision to meet its hardware and software requirements for serialisation at levels 1 (device level), 2 (line level) and 3 (site level). The complete serialisation solution will be implemented in 15 of Recipharm’s European locations and on more than 70 production lines. The company anticipates that a pilot showcase line will be operational from July 2016 to allow customers to view and trial Recipharm’s standard solution for serialisation and aggregation.

Staffan Widengren, Director Corporate Projects at Recipharm, said: “We have undertaken an extensive evaluation process to ensure we partner with experts that will allow us to best support our customers on their serialisation journeys. It was clear that Marchesini Group and SEA Vision have a very strong relationship, which would allow us to seamlessly implement the hardware and software required for serialisation”.

Pietro Tomasi, commercial director at Marchesini Group, said: “We are really pleased that a notable company such as Recipharm has chosen Marchesini Group to carry out this project. Our serialisation and track and trace solutions offer a high level of customisation and we look forward to working with Recipharm to ensure the company is well prepared for the new regulations.”

Marco Baietti, commercial director at SEA Vision, added: “As a CDMO, Recipharm is leading the way in preparing for serialisation and ensuring the challenge is high on its agenda. We are delighted to support the company on its serialisation journey and look forward to a successful partnership”.